Possibly—but it depends on who is requesting the expedited review and in which country/regulator.
If you mean adding a new indication or supplement request to the FDA
For Vascepa (icosapent ethyl), expedited processing is handled by the FDA via specific pathways (e.g., Fast Track, Breakthrough Therapy, Priority Review, Accelerated Approval). Those designations are based on the drug’s data and clinical benefit, not something most companies can simply request to “go faster” without meeting criteria.
What typically determines eligibility:
- Evidence of serious or life-threatening condition
- Potential for substantial improvement vs. existing therapy
- Strong trial results supporting the application goal
If you mean your personal access to Vascepa
FDA processing isn’t usually something patients can expedite. What you can do instead:
- Ask your prescriber for a prior authorization (PA) and submit it promptly (sometimes with supporting documentation).
- Request an expedited PA through your insurance (many plans allow faster review when there’s urgent need).
- Ask the pharmacy to use therapeutic alternatives if coverage is delayed (your clinician can advise).
If you mean a prescription refill / pharmacy order
There may be practical options like:
- Transfer the prescription
- Check insurance coverage or copay assistance
- Use a different formulation/strength if available (depends on your situation)
Quick question so I can give the right answer
When you say “expedite Vascepa’s application processing,” do you mean:
- FDA/marketing authorization for a new label/indication, or
- Insurance/pharmacy processing for your prescription, or
- Something else (e.g., a clinical trial, compounding, import, etc.)?
Tell me which one and your country (US/other), and I’ll point you to the most relevant process.